Aspire Biopharma director Surendra Ajjarapu resigns

Q: What did Aspire Biopharma Holdings, Inc. (ASBP) disclose in this 8-K?

The company disclosed that director Surendra Ajjarapu resigned from the Board of Directors, effective immediately on January 7, 2026.

Q: When did the Aspire Biopharma director resignation become effective?

The resignation of director Surendra Ajjarapu became effective immediately upon his notice on January 7, 2026.

Q: Which section of the 8-K covers the Aspire Biopharma board change?

The board change is disclosed under Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Q: What securities of Aspire Biopharma are listed on Nasdaq?

Aspire Biopharma lists its common stock, par value $0.0001 per share, under the symbol ASBP, and its warrants, each exercisable for one share of common stock, under the symbol ASBPW on The Nasdaq Stock Market LLC.

Aspire Biopharma Holdings, Inc. reported that on January 7, 2026, director Surendra Ajjarapu notified the Board of Directors of his decision to step down from his role as a Director, effective immediately.

Accepted by SEC EDGAR 01/13/2026 - 04:30 PM EST

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Aspire Biopharma Holdings, Inc. reported that on January 7, 2026, director Surendra Ajjarapu notified the Board of Directors of his decision to step down from his role as a Director, effective immediately. The company states that his resignation is not due to any disagreement with Aspire Biopharma, its Board of Directors, or any member of its management. The filing otherwise contains administrative details, including the company’s listing of its common stock and warrants on The Nasdaq Stock Market LLC.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aspire Biopharma Holdings, Inc. (ASBP) disclose in this 8-K?

The company disclosed that director Surendra Ajjarapu resigned from the Board of Directors, effective immediately on January 7, 2026.

Why did director Surendra Ajjarapu resign from Aspire Biopharma (ASBP)?

The company states that Mr. Ajjarapu’s decision to resign is not due to any disagreement with Aspire Biopharma, its Board of Directors, or any member of its management.

When did the Aspire Biopharma director resignation become effective?

The resignation of director Surendra Ajjarapu became effective immediately upon his notice on January 7, 2026.

Which section of the 8-K covers the Aspire Biopharma board change?

The board change is disclosed under Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

What securities of Aspire Biopharma are listed on Nasdaq?

Aspire Biopharma lists its common stock, par value $0.0001 per share, under the symbol ASBP, and its warrants, each exercisable for one share of common stock, under the symbol ASBPW on The Nasdaq Stock Market LLC.

Does the Aspire Biopharma 8-K mention any disagreements or disputes with the resigning director?

No. It explicitly states that Mr. Ajjarapu’s resignation is not due to any disagreement with the company, its Board of Directors, or management.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2026

ASPIRE BIOPHARMA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-41293

33-3467744

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

23150 Fashion Drive, Suite 230

Estero, Florida

33928

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (908) 987-3002

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	ASBP	The Nasdaq Stock Market LLC
Warrants, each exercisable for one share of common stock	ASBPW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 7, 2026, Surendra Ajjarapu, a Director of Aspire Biopharma Holdings, Inc. (the “Company”), notified the Board of Directors of his intention to step down from the role of Director, effective immediately. Mr. Ajjarapu’s decision to resign is not due to any disagreement with the Company, the Board of Directors, or any member of the Company’s management.

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ASPIRE BIOPHARMA HOLDINGS, INC.

Dated: January 13, 2026	By:	/s/ Kraig Higginson
		Kraig Higginson
		Chief Executive Officer

Source: View Original Filing on SEC EDGAR